Mobius Therapeutics Investigates Extending Mitosol Platform

Ed Timm, President and CEO of Mobius Therapeutics LLC, provided an update on the investigations into extending the company’s Mitosol platform, presently used to administer mitomycin-C in ab externo glaucoma surgery. Mitosol avoids the issues of sterility and stability of mitomycin-C made in compounding pharmacies. Mobius is investigating the use of the platform in refractive surgery.


Ed Timm

Ed Timm

Ed has more than 25 years experience in the surgical device/life science industry. He has initiated and/or grown sub-specialty franchises for multiple companies, to include American Hospital Supply Corporation, Applied Medical Resources, Storz Ophthalmics, and Given Imaging, Ltd.

View Full Profile